Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

July 11, 2015
Otsuka Holdings

U.S. FDA APPROVES OTSUKA AND LUNDBECK’S REXULTI® (BREXPIPRAZOLE) AS ADJUNCTIVE TREATMENT FOR ADULTS WITH MAJOR DEPRESSIVE DISORDER AND AS A TREATMENT FOR ADULTS WITH SCHIZOPHRENIA
July 6, 2015
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory obtained the marketing approval of antiseptics for external use “Olanedine”
July 1, 2015
Otsuka Pharmaceutical

Otsuka Pharmaceutical Continues the Overseas Distribution Expansion of POCARI SWEAT East Timor Market Official Launch July 1, 2015
June 26, 2015
Taiho Pharmaceutical

ZOSYN® Receives Approval for the Additional Indication of Febrile Neutropenia
June 24, 2015
Otsuka Pharmaceutical

Otsuka Pharmaceutical Enters Into Health Promotion Partnership Agreement with Saitama Prefecture
June 23, 2015
Otsuka Pharmaceutical

Renovation of POCARI SWEAT Factory at Tianjin Otsuka Beverage Co., Ltd. Visitor-friendly Factory Conveys the Importance of Ions and Fluid Replenishment
June 15, 2015
Taiho Pharmaceutical

Taiho Pharmaceutical Co., Ltd. and Servier Enter Into a License Agreement for Development and Commercialization of an Oral Anticancer Drug TAS-102 in Europe
June 1, 2015
Taiho Pharmaceutical

Support for modern people in the prime of life! Designated quasi-drug Tiovita Gold α (Alpha) mini-drink to be launched throughout Japan on June 22
May 28, 2015
Otsuka Pharmaceutical

Otsuka's JINARC® the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
May 20, 2015
Otsuka Pharmaceutical

Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong Otsuka Pharmaceutical to Launch Carbonated Nutritional Beverage in Rapidly Growing Hong Kong Market
May 20, 2015
Otsuka Pharmaceutical

New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25
May 14, 2015
Taiho Pharmaceutical

Results from Global Phase III Trial of TAS-102 (brand name in Japan: "Lonsurf® ") Published in The New England Journal of Medicine
April 30, 2015
Otsuka Holdings

Otsuka announces 2015 first quarter U.S. net sales figures of ABILIFY®
April 28, 2015
Otsuka Medical Devices

Establishment of New Company “Lilium Otsuka” to Develop Innovative Medical Devices in the Field of Urology
April 23, 2015
Otsuka Pharmaceutical

Kenja-no-shokutaku Double Support Makes Overseas Debut in Hong Kong
April 20, 2015
Otsuka Pharmaceutical

Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry
April 7, 2015
Otsuka Pharmaceutical

Review of research on use by menopausal women of nutritional supplement equol appears in US women's health publication
April 1, 2015
Otsuka Pharmaceutical

A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
March 30, 2015
Otsuka Pharmaceutical

Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
March 27, 2015
Otsuka Holdings

Otsuka Holdings Announces Change in Status of Representative Director
March 26, 2015
Otsuka Pharmaceutical

Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures
March 26, 2015
Otsuka Pharmaceutical

Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia
March 26, 2015
Otsuka Pharmaceutical

New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
March 26, 2015
Otsuka Holdings

Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY – ABILIFY for Extended–release Injectable Suspension, for Intramuscular Use – Indicated for Schizophrenia
March 20, 2015
Taiho Pharmaceutical

Lonsurf® Combination Tablet for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer Receives Approval in Japan for Partial Change in Indications
March 19, 2015
Otsuka Pharmaceutical

The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
March 18, 2015
Otsuka Pharmaceutical

Celebrating 50 Years of ORONAMIN C DRINK
March 10, 2015
Otsuka Pharmaceutical

New SOYJOY With More Fruit! Renewed Strawberry and Blueberry Versions Contain More Fruit
March 6, 2015
Otsuka Pharmaceutical

Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors
March 2, 2015
Otsuka Pharmaceutical

Otsuka Pharmaceutical, Otsuka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales